What, exactly, are the new ACC AHA Cholesterol Guidelines? The PREVENT calculator, LDL-C targets, and expanded screening
The American College of Cardiology and the American Heart Association have released the 2026 Dyslipidemia Guidelines, a major update that overhauls how doctors calculate cardiovascular risk.
The American College of Cardiology (ACC) and the American Heart Association (AHA) have officially published their 2026 dyslipidemia guidelines, marking the first major update to the nation's cholesterol management standards since 2018. Now, millions are suddenly wondering what the latest science means for their heart health and daily routines.
For the first time since 2018, the country's top cardiovascular experts have overhauled the rulebook on managing cholesterol. In fact, they have broadened the scope entirely, renaming it a "dyslipidemia" guideline to capture a wider range of dangerous blood fats beyond just traditional cholesterol.
This isn't just a minor tweak for doctors. The 2026 update fundamentally shifts how early we should worry about heart disease, the formulas used to calculate our risk, and the exact numerical targets we should be aiming for.
Here is a breakdown of what the new guidelines actually do, who they affect, and what you might want to ask at your next checkup.
| Dyslipidemia Guidelines | Quick Reference for 2026 |
|---|---|
| What they do | Replace the old risk calculator with the PREVENT-ASCVD tool, reintroduce strict numerical LDL-C targets (e.g., aiming <55 mg/dL for the highest-risk patients), and emphasize earlier, more aggressive lipid-lowering therapies over a lifetime. |
| Who they affect | Almost everyone. Universal screening is now recommended for children starting at ages 9-11. For adults, the threshold for medical intervention has been lowered, meaning millions with a "borderline" risk (as low as 3%) might now be recommended preventative medication. |
| What to ask at your next checkup | "What is my 10-year risk using the new PREVENT calculator?" "Should I get a one-time Lipoprotein(a) test?" "Would a Coronary Artery Calcium (CAC) scan help clarify if I actually need a statin?" |
Sources & References
The information in this article was sourced from the "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia."
This clinical practice guideline is a joint report developed by the American College of Cardiology and the American Heart Association, in collaboration with multiple other national medical societies. The report, chaired by Dr. Roger S. Blumenthal, was published in the Journal of the American College of Cardiology (JACC) in 2026.
The Shift to PREVENT-ASCVD: A New Way to Calculate Heart Disease Risk
For years, doctors have used a tool called the Pooled Cohort Equations to predict your chances of a major heart event over the next decade. The 2026 guidelines toss that out.
Clinicians must now "...use the more contemporary American Heart Association Predicting Risk of cardiovascular disease EVENTS (PREVENT™) equations instead of the older Pooled Cohort Equations (PCE) for 10- and 30-year risk assessment to guide lipid-lowering therapy."
This new calculator is built on contemporary data and generally estimates a slightly lower, more accurate risk profile than the old math. With this new formula, the threshold for action has shifted.
Now, a 10-year risk estimate as low as 3% might be enough to kickstart a conversation about preventative medication, down from the previous threshold of 5%.
The CPR Framework: Calculate, Personalize, Reclassify
To navigate this, the medical societies introduced a simple three-step approach for clinicians assessing primary prevention, known as the CPR framework:
- Calculate: Run the numbers using the PREVENT tool.
- Personalize: Look at "risk enhancers" not captured by the basic math. This includes things like autoimmune diseases, a history of preeclampsia or premature menopause, or a strong family history of early heart disease.
- Reclassify: If the decision to start medication is still up in the air, doctors are heavily encouraged to use a Coronary Artery Calcium (CAC) scan. This quick imaging test can confirm if plaque is already building up—or if the arteries are clear, which might let you safely delay medication.
Target LDL-C Levels: 2026 ACC AHA Cholesterol Guidelines Chart
Here is a breakdown of the target numbers based on a patient's risk category:
| Patient Population | Target LDL-C Level | Target Non-HDL-C Level |
|---|---|---|
| Primary Prevention (PREVENT-ASCVD <10% risk) | <100 mg/dL | <130 mg/dL |
| Primary Prevention (PREVENT-ASCVD ≥10% risk) | <70 mg/dL | <100 mg/dL |
| Secondary Prevention (Patients with existing ASCVD, not very high risk) | <70 mg/dL | <100 mg/dL |
| Secondary Prevention (Patients with existing ASCVD at very high risk) | <55 mg/dL | <85 mg/dL |
| Severe Hypercholesterolemia (No ASCVD risk factors) | <100 mg/dL | <130 mg/dL |
The previous guidelines largely focused on reducing your baseline cholesterol by a certain percentage. Now, strict numerical targets have made a comeback. As the report notes, "LDL-C and non-high-density lipoprotein cholesterol (HDL-C) treatment goals are back to guide LLT."
The overarching message is that lower is better. Getting to these target numbers might require layering newer, non-statin medications—like PCSK9 inhibitors or bempedoic acid—on top of traditional statins.
Expanded Screening and the Focus on Lifetime Exposure
Perhaps the most significant philosophical shift is the focus on lifetime exposure. The report is clear about its primary directive: "Treat dyslipidemia earlier to reduce lifelong risk of prolonged exposure to atherogenic lipoproteins."
Because the longer these fats circulate in your blood, the more damage they do over time, the guidelines push for earlier detection. Universal screening is recommended for children between 9 and 11 to catch genetic cholesterol disorders, and adults should get a routine baseline check starting at age 19.
The update also throws a spotlight on two specific biomarkers:
- Lipoprotein(a): Also known as Lp(a), this is a genetic variant of bad cholesterol that significantly drives up heart risk. The guidelines now recommend everyone get this tested at least once in their life.
- Apolipoprotein B (ApoB): This test measures the actual number of plaque-building particles in your blood. It gives a clearer picture of your risk even if your standard LDL cholesterol looks "normal"—a scenario especially common in people with diabetes or high triglycerides.
Looking Ahead: What do the
The 2026 guidelines represent a shift toward highly proactive cardiovascular care. While diet, exercise, and weight management remain the bedrock of heart health, the medical community is moving toward earlier, more personalized, and more aggressive interventions to keep arteries clear for a lifetime.
